ATE316791T1 - Stimulierung von wirtseigenen abwehrmechanismen gegen tumore - Google Patents

Stimulierung von wirtseigenen abwehrmechanismen gegen tumore

Info

Publication number
ATE316791T1
ATE316791T1 AT97920907T AT97920907T ATE316791T1 AT E316791 T1 ATE316791 T1 AT E316791T1 AT 97920907 T AT97920907 T AT 97920907T AT 97920907 T AT97920907 T AT 97920907T AT E316791 T1 ATE316791 T1 AT E316791T1
Authority
AT
Austria
Prior art keywords
stimulation
host
defense mechanisms
against tumors
mechanisms against
Prior art date
Application number
AT97920907T
Other languages
German (de)
English (en)
Inventor
Michael Gerard Tovey
Thomas James Kaido
Original Assignee
Pharma Pacific Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharma Pacific Pty Ltd filed Critical Pharma Pacific Pty Ltd
Application granted granted Critical
Publication of ATE316791T1 publication Critical patent/ATE316791T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/41—Porphyrin- or corrin-ring-containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • AIDS & HIV (AREA)
  • Biotechnology (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Reproductive Health (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
AT97920907T 1996-05-09 1997-05-05 Stimulierung von wirtseigenen abwehrmechanismen gegen tumore ATE316791T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AUPN9765A AUPN976596A0 (en) 1996-05-09 1996-05-09 Stimulation of host defence mechanisms

Publications (1)

Publication Number Publication Date
ATE316791T1 true ATE316791T1 (de) 2006-02-15

Family

ID=3794078

Family Applications (2)

Application Number Title Priority Date Filing Date
AT97920907T ATE316791T1 (de) 1996-05-09 1997-05-05 Stimulierung von wirtseigenen abwehrmechanismen gegen tumore
AT97919563T ATE316793T1 (de) 1996-05-09 1997-05-05 Stimulierung wirtseigener abwehrmechanismen gegen virusangriffe

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT97919563T ATE316793T1 (de) 1996-05-09 1997-05-05 Stimulierung wirtseigener abwehrmechanismen gegen virusangriffe

Country Status (17)

Country Link
EP (2) EP0956040B1 (OSRAM)
JP (2) JP3806444B2 (OSRAM)
KR (2) KR100399499B1 (OSRAM)
CN (1) CN1154508C (OSRAM)
AR (2) AR007058A1 (OSRAM)
AT (2) ATE316791T1 (OSRAM)
AU (3) AUPN976596A0 (OSRAM)
BR (2) BR9709223A (OSRAM)
CA (2) CA2253908A1 (OSRAM)
DE (2) DE69735201T2 (OSRAM)
ES (2) ES2260794T3 (OSRAM)
ID (2) ID16886A (OSRAM)
IL (2) IL126972A0 (OSRAM)
NZ (2) NZ332688A (OSRAM)
TW (1) TW528599B (OSRAM)
WO (2) WO1997041886A1 (OSRAM)
ZA (1) ZA973988B (OSRAM)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6299871B1 (en) * 1998-07-24 2001-10-09 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Orally-administrable therapeutic and/or prophylactic agent for HTLV-1-related diseases
JP2003500113A (ja) * 1999-05-26 2003-01-07 ザ ブリガム アンド ウイミンズ ホスピタル、 インコーポレイテッド アルファ平滑筋アクチン活性を調節する薬剤の治療的使用
US6710025B1 (en) 1999-05-26 2004-03-23 The Brigham And Women's Hospital, Inc. Treatment of damaged tissue using agents that modulate the activity of alpha-smooth muscle actin
US20040258663A1 (en) * 2003-05-08 2004-12-23 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of interferon alpha
ATE374838T1 (de) 2004-04-29 2007-10-15 Hoffmann La Roche Nukleotidsequenzvariation im gen ns5a als marker
DE102007014752A1 (de) 2007-03-28 2008-10-02 Dusek, Niels, Dr. Verwendung von humanidentischem oder humanaequivalentem rekombinantem Interleukin-2 (heqlL-2) als Therapeutikum in der Human- und Veterinärmedizin

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0058192A1 (en) * 1980-08-22 1982-08-25 University of Illinois Foundation Delivery of biologically active components of heterologous species interferon isolates
US5286748A (en) * 1981-01-05 1994-02-15 Eby Iii George A General method of shortening the duration of common colds by application of medicaments to tissues of oral cavity
US4820515A (en) * 1982-12-13 1989-04-11 Texas A&M University System Method of using interferon in low dosage to regulate appetite and efficiency of food utilization
US4605555A (en) * 1984-09-20 1986-08-12 Sun Star Kabushiki Kaisha Composition and method for treating keratosic disorder of skin and mucosa
IL76591A0 (en) * 1984-10-05 1986-02-28 Bioferon Biochem Substanz Pharmaceutical compositions containing ifn-ypsilon and processes for the preparation thereof
ZA878295B (en) * 1986-11-06 1988-05-03 Amarillo Cell Culture Co. Inc. Treatment of immuno-resistant disease
JP2704546B2 (ja) * 1989-04-04 1998-01-26 光利 太良 Ａｔｌｌ治療用吸入剤
US5372808A (en) * 1990-10-17 1994-12-13 Amgen Inc. Methods and compositions for the treatment of diseases with consensus interferon while reducing side effect
US5215741A (en) * 1990-10-30 1993-06-01 Amarillo Cell Culture Company, Incorporated Method for prevention of parasite infections
EP0563177A1 (en) * 1990-12-14 1993-10-06 Schering Corporation Oral administration of alpha interferon to treat lung malignancies
US5780021A (en) * 1993-03-05 1998-07-14 Georgetown University Method for treating type 1 diabetes using α-interferon and/or β-i
IL113280A (en) * 1994-04-12 2004-12-15 Res Dev Foundation A preparation for the treatment of self-immunization diseases with the help of interferon of one type
NZ332689A (en) * 1996-05-09 2000-07-28 Pharma Pacific Pty Ltd Using interferon to treat autoimmune, mycobacterial or neurodegenerative disease

Also Published As

Publication number Publication date
NZ332688A (en) 2000-07-28
DE69735201T2 (de) 2006-09-21
NZ332690A (en) 2000-07-28
ID16886A (id) 1997-11-20
EP0898478B1 (en) 2006-02-01
KR100399499B1 (ko) 2003-12-18
KR20000010880A (ko) 2000-02-25
ES2260790T3 (es) 2006-11-01
IL126972A0 (en) 1999-09-22
EP0898478A1 (en) 1999-03-03
DE69735201D1 (de) 2006-04-13
DE69735204D1 (de) 2006-04-13
EP0956040B1 (en) 2006-02-01
KR20000010882A (ko) 2000-02-25
JP3806444B2 (ja) 2006-08-09
CA2253908A1 (en) 1997-11-13
EP0956040A4 (OSRAM) 1999-11-17
IL126970A0 (en) 1999-09-22
ZA973988B (en) 1998-11-09
ATE316793T1 (de) 2006-02-15
EP0956040A1 (en) 1999-11-17
TW528599B (en) 2003-04-21
KR100399501B1 (ko) 2003-12-18
CN1154508C (zh) 2004-06-23
WO1997041883A1 (en) 1997-11-13
EP0898478A4 (en) 1999-05-26
WO1997041886A1 (en) 1997-11-13
JP2000504027A (ja) 2000-04-04
CA2253902A1 (en) 1997-11-13
BR9709066A (pt) 2000-01-04
AU2710997A (en) 1997-11-26
JP3806446B2 (ja) 2006-08-09
ID16885A (id) 1997-11-20
AU724190B2 (en) 2000-09-14
JP2000504026A (ja) 2000-04-04
AU729514B2 (en) 2001-02-01
AR007058A1 (es) 1999-10-13
BR9709223A (pt) 2000-12-12
AUPN976596A0 (en) 1996-05-30
DE69735204T2 (de) 2006-09-21
CN1218409A (zh) 1999-06-02
ES2260794T3 (es) 2006-11-01
AU2399297A (en) 1997-11-26
AR007059A1 (es) 1999-10-13

Similar Documents

Publication Publication Date Title
EP0789592A4 (en) Ocular gene therapy
DE69700689D1 (de) Kosmetische Zusammensetzung von Augenschminke
DE69428978D1 (de) Parfümierungsverfahren von geweben
DE69518305D1 (de) Herzschrittmacher mit universalem überzug
DE69528131D1 (de) Kosmetische Präparate
FI941459A7 (fi) Tuumorinekroositekijän muteiineja
DE69111852D1 (de) Plättchenförmiges Bariumsulfat und kosmetische Zusammensetzung.
DE69824170D1 (de) Ratenstabilisierender herzschrittmacher
FI965204A0 (fi) Bromelaiinin lääkekäyttö
DE19781819T1 (de) Kardiale Schrittmacher-Anschlußvorrichtung
DE69501945D1 (de) Konditionierung von geweben
ZA973987B (en) Stimulation of host defence mechanisms against viral challenges
DE69738597D1 (de) Vakzine gegen das varicella zostervirus produkt von gen 63
DE69735204D1 (de) Stimulierung von wirtseigenen abwehrmechanismen gegen tumore
DE68906245D1 (de) Therapeutisches mittel gegen aids.
FI963263A0 (fi) Bromelaiinin lääkinnällinen käyttö
DE69710305D1 (de) Derivate von 4-Vinyl-4'-alpha-hydroxyethyl-biphenyl
DE68927340D1 (de) Biologischer impfstoff, wirksam gegen aphanomyces
NO996496D0 (no) (S) 2-metylamino-2-fenyl-n-butyl 3,4,5-trimetoksybenzoat samt anvendelse av denne ved behandling av kronisk smerte
NO990303L (no) Lipidbindende proteiner og deres terapeutiske og diagnostiske anvendelse
KR940021953U (ko) 휴지걸이
RU97111990A (ru) Обезболивающее и противозудное средство
KR950016727U (ko) 온침치료기
KR910016405U (ko) 휴대용 티슈
LV11523A (lv) Domperidona pielietosana kardalgijas arstesana

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0898478

Country of ref document: EP

REN Ceased due to non-payment of the annual fee